ACCELERATING DRUG DISCOVERY. TODAY.

 

 

TRULY QUANTITATIVE 

HIGHLY SENSITIVE

> BROAD DYNAMIC RANGE

 

OUR TECHNOLOGY

01 / FAST

Biomolex has developed a unique technology that allows for faster image acquisition than conventional technology.

02 / HIGH RESOLUTION

Our radiographic labelling of molecules allows for a higher resolution than conventional molecular imaging.

03 / DISRUPTIVE

Our system aims to transform the drug discovery process, starting with kinase drug targets for oncology. 

Double Sided Silicon Strip

Superior Image Quality and Detail

Competitor Imager

72 hours

Biomolex Imager

72 hours

IMAGE GALLERY

Biomolex 700 Instrument
© 2001-2016, Biomolex AS
Biomolex 700 - Slide Wrapper
© 2001-2016, Biomolex AS
PepChip® Kinase substrate array
Slide incubated with cell-lysate and P33 labelled ATP. © 2001-2016, Biomolex AS.
Line Profile, DSSD System
Top: Digital autoradiography images of the same sample of segments of 18 μm thick wires, showing the Co-58 activity from the DSSD system for 93h (A), and a storage phosphor screen system for 144h, scanned at 600dpi (B). Background was subtracted and both images were individually scaled from zero (white) to max (black) intensity. Bottom: examples of intensity line profiles from one of the lines in the images above, measured using the DSSD system (C) and the phosphor screen (D). © 2013, A. Örbom
Eye in Black & White
© 2001-2016, Biomolex AS.
Aorta: Oil Red O vs. Biomolex 700
From left to right, the animal aorta was stained with Oil Red O to identify the lipid deposits followed by the processed Oil Red O image to define plaque and non-plaque areas. Finally, with a 5x5-pixel mean filter applied, digital autoradiography images of the same aorta, separated into contributions from the different radiotracers. Each image is individually scaled from zero (white) to max (black) uptake and does not reflect differences in total uptake between tracers. © 2013, Anders Örbom.
Show More

MEET BIOMOLEX

OUR STORY

Biomolex AS is a Norwegian biotech company that was established as a joint venture between The Norwegian Radium Hospital (NRH) and Ideas ASA (Ideas) in May 2001. Biomolex has developed a unique patented microarray reader - an imaging system for gene and protein analysis.

OUR VISION

We provide tools that accelerate drug discovery, enable precision medicine and increase the quality of data in research. Our vision is to become a unique supplier of kinase arrays for diagnostics and drug development.

OUR TECHNOLOGY

The Biomolex digital radiography system provides real time detection of multiple radioisotope labels. With a higher sensitivity than classical phosphorimagers, we aim to make molecular imaging more precise.

MANAGEMENT

Eirik Næss-Ulseth

Chairman of the Board

Håvard Hildeng Hauge

Chief Executive Officer

 

USING BIOMOLEX 700

 

3D distribution of labeled antibody; CD20+ tumor (I-131)

 

Imaging provided by UCLA

GET IN TOUCH

Tel:  +47 22 14 70 87   

Fax: +47 22 13 79 11

Klaus Torgårds Vei 3 – 0372

Oslo – Norway

 

REQUEST A DEMO

Please fill your contact details below:
 
LINKS
ABOUT

© 2001-2021 by Biomolex AS. All rights reserved.

Håvard H. Hauge

Dr. Hauge, CEO of Biomolex, has been with the company since incorporation in 2001. He holds a Ph.D. in biochemistry from the U of Oslo. Mr. Hauge completed his Postdoc at the Biochemistry department, University of Oslo and EMBL, Heidelberg. During his Postdoc he worked on several protein NMR structure projects. Mr. Hauge has a strong scientific background and can assist and guide customers in designing and setting up advanced experiments and application protocols for the Biomolex instrument.